Dopamine and Insulin Resistance

NCT00802204 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2017-05-10

Study results available
· View outcomes & findings →

Summary

Obese individuals have fewer striatal dopamine type 2 receptors (DRD2) than normal weight individuals. Lower DRD2 levels are associated with addiction and a decreased sense of pleasure.Obesity is also associated with insulin resistance (poor insulin action).We propose that insulin resistance and low DRD2 are associated. Using PET imaging,we aim to determine DRD2 binding potential (BP) in the brain is associated with insulin resistance and neuroendocrine hormone levels. Obese participants will be compared to lean, gender and age similar participants. We also aim to determine the effect of caloric restriction on DRD2 BP in obese subjects

Conditions

Interventions

RADIATION

PET scan

Both lean and obese undergo a PET scan of the brain using the radioligand,fallypride \[18F\] at baseline. Obese subjects who complete caloric restriction will have repeat scan after diet. Completed at baseline and post-VLCD

PROCEDURE

Oral glucose tolerance test

Subjects will be required to drink a glucose solution; blood samples will be taken over a 5-hour time period Completed at baseline by both lean and obese and in obese post-VLCD

PROCEDURE

MRI

An MRI of the brain and abdomen will be performed prior to PET scan One time at baseline in both lean and obese

BEHAVIORAL

Psychological scales to assess attitudes and behaviors related to eating and quality of life

A series of short psychological scales will be administered during the study. Completed at baseline

OTHER

Caloric Restriction

Obese participants only complete a short-term (\~10days) very low calorie diet

Sponsors & Collaborators

  • Vanderbilt University

    lead OTHER

Principal Investigators

  • Julia P Dunn, MD · Vanderbilt University Medical Center

  • Robert M Kessler, MD · Vanderbilt University Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2011-04-30
Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00802204 on ClinicalTrials.gov